Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly

Treasury yields surged, with the 10-year near 5.15% and the 30-year at 5.458%, while fed-funds futures priced a 68.6% probability of an October rate hike, up from roughly 55% a week earlier. Brent crude rose as high as $108/bbl, adding pressure on consumers, though reports of a possible U.S.-Iran agreement to reopen the Strait of Hormuz helped the S&P 500 and Nasdaq rebound from intraday declines of 0.5% and 0.av不卡免费播放8%, respectively. Starbucks will close roughly 250 North American cafes, take about $300M of restructuring charges, and cut fiscal-2026 net new-store openings to 440 from 600-650; Eli Lilly gained more than 3% after FDA approval of weekly insulin Onswik, although consensus expects the product to contribute less than 1% of Lilly's 2030 sales.

Analysis

The dominant cross-asset signal is the simultaneous rise in real-rate discounting and energy-driven consumer pressure, not the company-specific headlines. At a 5%+ long-end yield, duration-sensitive consumer compounders face multiple compression even if operating execution improves; SBUX’s portfolio rationalization can lift four-wall margins, but the valuation recovery requires evidence that transferred sales offset lost revenue and that transaction trends stabilize. COST is more defensively positioned on traffic and membership economics, yet its premium multiple remains exposed to a higher-for-longer rate regime; post-results guidance on renewal, SG&A, and discretionary general merchandise matters more than the reported quarter.

SBUX closures may create localized share opportunities for QSR and convenience operators—MCD, YUM and DPZ—but only where closures are not clustered near remaining Starbucks stores. The near-term benefit is likely modest: closure charges depress reported earnings, while lease exits and labor redeployment can delay margin realization by 1-3 quarters. The key falsifier is negative North American comparable transactions persisting through the next two earnings prints; that would indicate demand leakage rather than sales transfer.

LLY’s weekly-insulin approval is strategically more relevant as a payer-contracting and diabetes-prescriber relationship tool than as a standalone revenue driver. It marginally reduces NVO’s ability to differentiate on dosing convenience, but neither stock’s valuation changes absent GLP-1 supply, formulary access, or trial-data developments. A more actionable structural theme is China licensing: escalating deal competition can inflate upfront payments and lower future pipeline IRRs for large pharma, creating a medium-term capital-allocation risk rather than an immediate catalyst.

The reported Hormuz optimism should be treated as fragile: any reversal that sustains oil strength would tighten financial conditions through inflation expectations, hurting SBUX/COST discretionary multiples while supporting energy. Conversely, a softer consumer-sentiment reading paired with easing yields would likely generate the sharper near-term rebound in beaten-down COST and SBUX than their idiosyncratic news alone warrants.

Key Decisions for Investors

• Maintain a 1-3 month defensive pair: long COST / short SBUX in equal dollar amounts until SBUX demonstrates stable North American transactions and quantifies closure sales transfer. COST has stronger recurring membership cash flows; exit if COST renewal trends weaken materially or SBUX guides to clear transaction-led comp acceleration.
• Do not chase LLY on the insulin approval. Use any 5-8% GLP-1-driven pullback over the next 1-3 months to accumulate LLY versus NVO; the thesis requires continued obesity-drug supply expansion and favorable payer access, and is falsified by a material GLP-1 guidance cut or adverse reimbursement action.
• Ahead of COST earnings, avoid unhedged upside exposure at a still rate-sensitive valuation. A defined-risk watch trade is a post-print long only if renewal rates hold and operating-margin guidance absorbs wage/merchandise pressure; otherwise, a break in consumer metrics could drive a further 10% multiple reset over 1-3 months.
• Use XLE versus XLY as a tactical hedge while Brent remains elevated and long yields are above 5%. Reassess within days on credible de-escalation in Middle East shipping risk or a sustained Brent move below $95, either of which would remove the energy-inflation leg of the trade.